Ascletis to develop fixed-dose combination of ASC-48 and ASC-30

July 16, 2026

Ascletis Pharma Inc. has selected a fixed-dose combination of ASC-48, an oral small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, and ASC-30, an oral small-molecule glucagon-like peptide 1 receptor (GLP-1R) agonist, for clinical development for obesity.

BioWorld Science Endocrine/metabolic

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...